Total Synthesis of Ferrugine and Synthetic Studies Towards Ferruginine and Stemofoline

Total Page:16

File Type:pdf, Size:1020Kb

Total Synthesis of Ferrugine and Synthetic Studies Towards Ferruginine and Stemofoline Total Synthesis of Ferrugine and Synthetic Studies Towards Ferruginine and Stemofoline by Shamim Ahmed A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY School of Chemistry ( University of Birmingham August 2009 1 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Acknowledgements Firstly, I would like to acknowledge my supervisor Dr. Richard Grainger for his continued support and endless guidance throughout my PhD. In particular, I am grateful to him for making me believe in myself during the good, the bad and the ugly times. I am forever grateful to my special wife Nilupa for her everlasting enthusiasm, encouragement, guidance and the level of support received throughout this tough process. I would also like to express my gratitude to the past and present group members such as Luke, Katia, Emma, Bhaven, Tyrone and Benedicte for their support and entertainment over the last few years. I am also grateful to the analytical facility for their assistance, in particular Dr Neil Spencer for NMR, Pete Ashton, and Nick May for mass spectrometry and Dr Benson Kariuki for X-Ray crystallography. Finally, I would like to thank my friends and family including the entire Hassan family for their patience, in particular my parents and sister Sabina, Morzina and Anjuna for humouring me at all times. 2 Abstract Tropane alkaloids, containing the 8-azabicyclo[3.2.1]octane ring system, are widespread in Nature. This thesis describes the total synthesis of the tropane alkaloid ferrugine, isolated from the arboreal species Darlingiana ferruginea and attempted synthesis of ferruginine, isolated from the arboreal species D. darlingiana. Formation of a bridged 6-azabicyclic-[3.2.2]-ring system was achieved using a transannular photomediated cyclisation of a carbamoyl radical, generated from a carbamoyl diethyldithiocarbamate, onto an unactivated pendant alkene, followed by group transfer of the dithiocarbamate moiety. The carbamoyl radical cyclisation precursor was synthesised from a known seven-membered ring carboxylic acid. The diastereomeric dithiocarbamates converged to a single alkene upon thermal elimination. Addition of phenyllithium to the amide followed by base-mediated skeletal rearrangement resulted in the total synthesis of the natural product ferrugine, and using a similar strategy the core structure of ferruginine was secured. The stemona alkaloid stemofoline is characterised by a complex azatricyclic ring system unique to this class of natural products. Synthetic efforts have been made toward the synthesis of a cyclisation precursor required for the assembly of this azatricyclic framework, via a proposed tandem 7-endo-trig/5-exo-trig carbamoyl radical cyclisation. The synthesis commenced with the commercially available dimethyl 3,3-thiodipropanoate which was further elaborated and coupled with 5-hepten-2-one to provide an advanced intermediate enone. Addition of ammonia gave a pyrroline which was condensed with triphosgene followed by sodium diethyldithiocarbamate to produce a carbamoyl radical precursor. Unfortunately, efforts towards oxidation and elimination of the sulfide to obtain an α,β-unsaturated ketone proved ineffective. Attempted carbamoyl radical cyclisation-dithiocarbamate group transfer onto enones and nitriles are also presented. 3 ABBREVIATIONS Ac acetyl Bn benzyl Boc t-butoxycarbonyl Bu butyl CI chemical ionisation °C degrees centigrade cat. catalytic cm3 cubic centimetres DBU 1,8-diazabicyclo[5.4.0] undecene DIBAH diisobutylaluminium hydride DIPEA diisopropylethylamine DPPA diphenylphosphorylazide DMAP 4-dimethylamino pyridine DMPU 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)- pyrimidinone DMSO dimethylsulfoxide DMF N,N-dimethylformamide de diastereomeric excess ee enantiomeric excess EI electron impact ESI electron spray ionisation Et ethyl g grams GC gas chromatography h hours Hz hertz HMPA hexamethylphosphoramide i- iso- IBX 2-Iodoxybenzoic acid IR infrared spectrometry J coupling constant (Hz) 4 LDA lithium diisopropylamide LiHMDS lithium hexamethyldisilazide M molar Me methyl min. minutes mL millilitres mp melting point Ms methanesulfonyl MS mass spectrometry MPO 4-methoxypyridine-N-oxide n- normal- NMO 4-methylmorpholine N-oxide NMR nuclear magnetic resonance p- para- PCC pyridinium chlorochromate Ph phenyl ppm parts per million Pr propyl Rf retention factor rt room temperature s- secondary- sat. saturated t- tertiary- TBAF tetra-n-butylammonium fluoride TBDMS t-butyldimethylsilyl TIPS tri-isopropylsilyl Tf trifluoromethanesulfonyl TLC thin layer chromatography TMS trimethylsilyl Ts para-toluenesulfonyl 5 CONTENTS 1. Ferruginine: background and significance 1 Tropane alkaloids 2 Ferrugine: isolation and biological activity 3 Davies’ synthesis of ferruginine 4 Rigby’s synthesis of (+)-ferruginine 6 Rapoport’s synthesis of (+)-ferruginine & (-)-ferruginine 9 Ham’s formal synthesis of ferruginine 13 Husson’s synthesis of (+)-ferruginine 14 Bäckvall’s synthesis of ferruginine 16 Node’s synthesis of (+)-ferruginine & (-)-ferruginine 19 Aggarwal’s synthesis of (+)-ferruginine 22 Bick’s synthesis of (-)-ferrugine 24 2. Aims and Objectives 26 Carbamoyl radical chemistry 27 Proposed syntheses of ferrugine and ferruginine 32 Radical cyclisations 33 Proposed synthesis of stemofoline 35 3. Total synthesis of ferrugine and attempted synthesis of ferruginine 38 Synthesis of cyclisation precursor via carbamoyl chloride 39 Route to cyclisation precursor via imidazolide 42 Synthesis of an eight-membered ring cyclisation precursor 44 6 Carbamoyl radical cyclisation 46 Thermal elimination of dithiocarbamates 50 Tandem carbamoyl radical cyclisation-thermal elimination 52 Completion of the synthesis of ferrugine 53 Attempted synthesis of ferruginine 57 Conclusion and future work 68 4. Stemofoline: Background and significance 70 Stemona alkaloids 71 Stemofoline: isolation and biological activity 73 Overman’s synthesis of asparagamine A 74 Kende’s total synthesis of isostemofoline 79 Thomas’s efforts towards stemofoline 84 Gin’s approach towards stemofoline 91 Olivio’s synthesis of bicyclic γylidenetetronates 99 Smith’s approach to the synthesis of 2 substituted pyrrolidines 102 Livingstone’s stereocontrolled synthesis of bridged pyrrolizidines 106 5. Synthetic efforts towards stemofoline 109 Proposed synthesis of stemofoline 110 Route to cyclisation precursor via carbamoyl chloride 110 Route to cyclisation precursor via imidozolide 119 Proposed route to cyclisation precursor via Wittig olefination 121 Conclusion and future work 125 6. Study of carbamoyl radical cyclisations onto nitriles and enone s 126 Attempted carbamoyl radical cyclisation onto nitriles 127 7 Attempted carbamoyl radical cyclisation onto enones 128 7. Experimental section 131 8. References 179 Appendix: X-ray data for 168, 174 and ferrugine 197 8 1. FERRUGININE: BACKGROUND AND SIGNIFICANCE 1 Tropane alkaloids Tropane alkaloids are nitrogenous bicyclic organic compounds which have the 8- azabicyclo[3.2.1]octane skeleton. The nitrogen bridge is between C1 and C5, two asymmetric carbons but tropane is optically inactive due to symmetry (fig 1). 8 1 2 2 7 1 NMe Me N 8 3 4 5 6 3 7 5 4 6 Fig 1 Currently there are over two hundred tropane alkaloids known to occur in natural sources.1 They are naturally found in many members of the plant families including Solanaceae, Erythroxylaceae, Con-VolVulaceae, Proteaceae, Rhizophoraceae, Brassicaceae, and Euphorbiaceae. They are known for their toxic and important medicinal properties.2-5 Atropine, the racemic form of (-)-hyoscyamine, was first isolated from atropa belladonna in 1833, while (- )-hyoscyamine was also isolated in the same year from hyoscyamus niger.1 These tropane alkaloids are muscarinic receptor agonist that are involved in constriction of the pupil and vasodilation. They are also responsible for moderating the heartbeat and stimulating secretions. While the notorious cocaine, isolated from the dried leaves of erythroxylum coca, can be used for its anaesthetic properties and can also be prepared from its precursor and metabolite, ecogonine (fig 2).2,3 2 Me Me Me Me N N N O N O OMe OH O Ph OH OH OH O O O C H C6H5 6 5 H O H O atropine (-)-hyoscyamine (-)-cocaine (-)-ecogonine Fig 2 Ferrugine: isolation and biological activity The tropane alkaloid (+)-ferruginine (1) was isolated from the arboreal species Darlingiana ferruginea6 and D. darlingiana,7 and its unnatural isomer (-)-ferruginine (2) has been prepared from cocaine.6 Ferruginine is found to be a good agonist for the nicotine acetylcholine receptor (nAchR). Due to its biological activity coupled with an interesting molecular architecture, it has generated considerable synthetic interest culminating in several racemic and enantiospecific syntheses.7-15 Me Me O N N Me Me O (+)-ferruginine (-)-ferruginine From hereon, a comprehensive review of the syntheses of ferruginine will be presented outlining the key chemical transformations involved. 3 Davies synthesis of ferruginine.8 Davies
Recommended publications
  • United States Patent (19) 11 Patent Number: 4,822,930 Liu 45 Date of Patent: Apr
    United States Patent (19) 11 Patent Number: 4,822,930 Liu 45 Date of Patent: Apr. 18, 1989 (54) PROCESS FOR PREPARING 3,890,326 6/1975 Tobin .................................. 570/206 MONOBROMINATED CYCLOBUTARENES 4,540,763 9/1985 Kirchhoff............................ 526/281 (75) Inventor: Ming-Biann Liu, Midland, Mich. OTHER PUBLICATIONS (73) Assignee: The Dow Chemical Company, Lloyd et al., "The Electrophilic Substitution of Ben Midland, Mich. zocyclobutene-II', Tetrahedron, 1965, vol. 21, pp. 245 (21) Appl. No.: 64,714 to 254. Lloyd et al., "Tetrahedron', vol. 20, pp. 2184-2194 22) Filed: Jun. 22, 1987 (1964). (51) Int. Cl'....................... C07C21/24: CO7C 17/00 52 U.S. C. .................................... 570/206; 570/207; Primary Examiner-Werren B. Lone 570/208; 570/209; 570/211 57 ABSTRACT 58) Field of Search ............... 570/206, 207,208, 209, Monobrominated cyclobutarenes are prepared by bro 570/210 minating a cyclobutarene in the presence of an organic (56) References Cited complexing agent, an acid scavenger, or water. Faster U.S. PATENT DOCUMENTS reaction rates highly selective to monobrominated cy clobutarenes are obtained without conventional heavy 3,420,035 2/1969 Bremmer ............................. 570/206 metal or halogen catalysts. 3,607,883 9/1971 Schneider ........ ... 570/206 3,755,444 8/1973 Schneider et al. .................. 570/206 3,763,248 10/1973 Mitchell .............................. 570/206 32 Claims, No Drawings 4,822,930 1. 2 high performance monomeric and polymeric composi PROCESS FOR PREPARNG tions for the electronics industry. MONOBROMINATED CYCLOBUTARENES DETALED DESCRIPTION OF THE BACKGROUND OF THE INVENTION 5 INVENTION This invention relates to a process for preparing bro As the term is used herein, "cyclobutarene' refers to minated organic compounds.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.414,133 B2 Stössel Et Al
    USOO7414133B2 (12) United States Patent (10) Patent No.: US 7.414,133 B2 Stössel et al. (45) Date of Patent: Aug. 19, 2008 (54) PALLADIUMAND PLATINUM COMPLEXES (58) Field of Classification Search ..................... 546/2: 549/3, 206; 313/504; 257/40: 528/423; (75) Inventors: Philipp Stössel, Frankfurt (DE); Ingrid 526/265 Bach, Bad Soden (DE); Hubert See application file for complete search history. Spreitzer, Viernheim (DE) (56) References Cited (73) Assignee: Merck Patent GmbH U.S. PATENT DOCUMENTS 4,539,507 A 9/1985 VanSlyke et al. (*) Notice: Subject to any disclaimer, the term of this 5,151,629 A 9/1992 VanSlyke patent is extended or adjusted under 35 5,621,131 A 4/1997 Kreuder et al. U.S.C. 154(b) by 637 days. 5,679,760 A 10, 1997 Mullen et al. 5,763,636 A 6/1998 Kreuder et al. (21) Appl. No.: 10/534,173 6,653,438 B1 1 1/2003 Spreitzer et al. 2004/O1384.55 A1 7/2004 Stossel et al. (22) PCT Filed: Nov. 4, 2003 FOREIGN PATENT DOCUMENTS EP O 707 O2O 4f1996 (86). PCT No.: PCT/EPO3/12279 EP O 842 208 5, 1998 EP O 894 107 2, 1999 S371 (c)(1), EP 1 O28 136 8, 2000 (2), (4) Date: May 6, 2005 EP 1 191 613 3, 2002 EP 1238981 9, 2002 WO WO-92, 18552 10, 1992 (87) PCT Pub. No.: WO2004/041835 WO WO-O2, 15645 2, 2000 WO WO-OO.22026 4/2000 PCT Pub. Date: May 21, 2004 WO WO-O2/O68435 9, 2002 (65) Prior Publication Data Primary Examiner P.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,388,135 B1 L0chtman Et Al
    USOO6388135B1 (12) United States Patent (10) Patent No.: US 6,388,135 B1 L0chtman et al. (45) Date of Patent: May 14, 2002 (54) PREPARATION OF 4-BROMOANILINE WO WO 98/31681 7/1998 DERVATIVES WO WO 99/58509 11/1999 (75) Inventors: Rene Lochtman, Mannheim; Michael OTHER PUBLICATIONS Keil, Freinsheim; Joachim Gebhardt, Wachenheim; Michael Rack, Miller et al. “Methoden Der Organischen Chemie' Band Heidelberg; Wolfgang von Deyn, V/4 (1960) pp. 240–242 & 274-249. Neustadt, all of (DE) (73) Assignee: BASF Aktiengesellschaft, Primary Examiner Samuel Barts Ludwigshafen (DE) (74) Attorney, Agent, or Firm-Keil & Weinkauf (*) Notice: Subject to any disclaimer, the term of this (57) ABSTRACT patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. A process for preparing 4-bromoaniline derivatives of the formula I (21) Appl. No.: 09/894,006 (22) Filed: Jun. 29, 2001 Related U.S. Application Data Br R2 (60) Provisional application No. 60/219,410, filed on Jul. 20, 2000. (30) Foreign Application Priority Data Jun. 30, 2000 (DE) ......................................... 10O3O 975 where: (51) Int. Cl." .............................................. C07C 209/00 (52) U.S. Cl. ....................... 564/412; 548/240; 548/247; R" is C1-Co-alkyl, C-C-haloalkyl, C1-Co-alkoxy, 558/418 C-C-haloalkoxy, C-C-cycloalkyl, halogen (58) Field of Search .......................... 564/412; 548/240, R is C-C-alkyl, C-C-alkoxy, Ca-Cs-cycloalkyl, 548/247; 558/418 C-C-alkenyl, cyano or a heterocyclic radical is described. (56) References Cited FOREIGN PATENT DOCUMENTS CA 22783.31 7/1998 30 Claims, No Drawings US 6,388,135 B1 1 2 PREPARATION OF 4-BROMOANILINE which comprises reacting a compound of the formula II DERVATIVES II R1 The present application claims priority of prior provi sional application Serial No.
    [Show full text]
  • Reactive Polymers in Organic Synthesis; Ortho- Benzoquinone and Ortho-Dihydroxyphenyl Derived Polymer Reagents
    Louisiana State University LSU Digital Commons LSU Historical Dissertations and Theses Graduate School 1975 Reactive Polymers in Organic Synthesis; Ortho- Benzoquinone and Ortho-Dihydroxyphenyl Derived Polymer Reagents. Dwight Crawford Kaufman Louisiana State University and Agricultural & Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses Recommended Citation Kaufman, Dwight Crawford, "Reactive Polymers in Organic Synthesis; Ortho-Benzoquinone and Ortho-Dihydroxyphenyl Derived Polymer Reagents." (1975). LSU Historical Dissertations and Theses. 2838. https://digitalcommons.lsu.edu/gradschool_disstheses/2838 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact [email protected]. INFORMATION TO USERS This material was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted. The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction. 1. The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity. 2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image.
    [Show full text]
  • Synthesis of 5-Substituted 7-Azaindoles and 7-Azaindolines
    (19) & (11) EP 1 633 750 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 471/04 (2006.01) 01.12.2010 Bulletin 2010/48 (86) International application number: (21) Application number: 04717703.5 PCT/GB2004/000946 (22) Date of filing: 05.03.2004 (87) International publication number: WO 2004/078757 (16.09.2004 Gazette 2004/38) (54) SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES SYNTHESE VON 5-SUBSTITUIERTEN 7-AZAINDOLEN UND 7-AZAINDOLINEN SYNTHÈSE DE 7-AZAINDOLES ET 7-AZAINDOLINES SUBSTITUÈS EN POSITION 5 (84) Designated Contracting States: • BHATIA, G., AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Eisai London Research Labs. Ltd. HU IE IT LI LU MC NL PL PT RO SE SI SK TR London WC1E 6BT (GB) (30) Priority: 06.03.2003 GB 0305142 (74) Representative: Crooks, Elizabeth Caroline et al Kilburn & Strode LLP (43) Date of publication of application: 20 Red Lion Street 15.03.2006 Bulletin 2006/11 London WC1R 4PJ (GB) (73) Proprietor: Eisai R&D Management Co., Ltd. (56) References cited: Tokyo 112-8088 (JP) WO-A-03/000688 US-A- 5 705 515 (72) Inventors: •PI-TAICHOU, ET AL.: "Excited-State Amine- Imine • GRACZYK, P., Double Proton Transfer in 7-Azaindoline" J. Eisai London Research Labs. Ltd. PHYS. CHEM. B, vol. 104, 2000, pages 7818-7829, London WC1E 6BT (GB) XP002280766 • KHAN, A., • SANDERSON, P. E. J.; ET AL.: "Azaindoles: Eisai London Research Labs. Ltd. Moderately Basic P1 Groups for Enhancing the London WC1E 6BT (GB) Selectivity of Thrombin Inhibitors" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol.
    [Show full text]
  • Identification of 1,5-Naphthyridine Derivatives As a Novel Series of Potent and Selective TGF-Â Type I Receptor Inhibitors
    4494 J. Med. Chem. 2004, 47, 4494-4506 Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-â Type I Receptor Inhibitors Franc¸oise Gellibert,*,† James Woolven,‡ Marie-He´le`ne Fouchet,† Neil Mathews,§,| Helen Goodland,| Victoria Lovegrove,| Alain Laroze,† Van-Loc Nguyen,† Ste´phane Sautet,† Ruolan Wang,⊥ Cheryl Janson,#,× Ward Smith,∇,× Gae¨l Krysa,X Vale´rie Boullay,X Anne-Charlotte de Gouville,X Ste´phane Huet,X and David Hartley| Departments of Medicinal Chemistry and Biology, GlaxoSmithKline, 25-27 Avenue du Que´bec, 91951 Les Ulis, France, Discovery Research, Computational and Structural Science, and Department of Medicinal Chemistry, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom, Discovery Research, Assay Development and Compound Profiling, GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709, and Discovery Research, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406 Received January 30, 2004 Optimization of the screening hit 1 led to the identification of novel 1,5-naphthyridine aminothiazole and pyrazole derivatives, which are potent and selective inhibitors of the transforming growth factor-â type I receptor, ALK5. Compounds 15 and 19, which inhibited ALK5 autophosphorylation with IC50 ) 6 and 4 nM, respectively, showed potent activities in both binding and cellular assays and exhibited selectivity over p38 mitogen-activated protein kinase. The X-ray crystal structure of 19 in complex with human ALK5 is described, confirming the binding mode proposed from docking studies. Introduction Chart 1 Transforming growth factor (TGF-â) is a pluripotent cytokine involved in a variety of biological processes such as development, cell growth, differentiation, cell adhesion, migration, extracellular matrix (ECM) deposi- tion, and immune response regulation.1 This cytokine regulates not only the ECM deposition in response to tissue injury, thus contributing to the healing process, the GS domain.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.652,137 B2 Graczyk Et Al
    USOO7652137B2 (12) United States Patent (10) Patent No.: US 7.652,137 B2 Graczyk et al. (45) Date of Patent: Jan. 26, 2010 (54) SYNTHESIS OF 5 SUBSTITUTED WO WO-99,51233 10, 1999 7-AZANDOLES AND 7-AZANDOLINES WO WO-00,26210 5, 2000 WO WO-00,26211 5, 2000 (75) Inventors: Piotr Pawel Graczyk, London (GB); WO WO-OO,35909 6, 2000 Afzal Khan, London (GB); Gurpreet WO WO-00, 35921 A1 6, 2000 Singh Bhatia, London (GB) WO WO-OOf 43393 T 2000 WO WO-OO,56710 9, 2000 (73) Assignee: Eisai R & D Management Co., Ltd. WO WO-00,64449 11, 2000 (JP) WO WO-OOf 64872 11, 2000 WO WO-01/12609 2, 2001 (*) Notice: Subject to any disclaimer, the term of this WO WO-O 1/47922 T 2001 patent is extended or adjusted under 35 WO WO-01/49288 T 2001 U.S.C. 154(b) by 450 days. WO WO-O2/10137 2, 2002 WO WO-O2, 16359 2, 2002 (21) Appl No.: 10A548.162 WO WO-O2/O81475 10, 2002 y x- - - 9 WO WO-03/028724 4/2003 (22) PCT Filed: Mar. 5, 2004 WO WO-03/082868 10, 2003 WO WO-03/082869 10, 2003 (86). PCT No.: PCT/GB2OO4/OOO946 WO WO-2004/O16609 2, 2004 WO WO-2004/O16610 2, 2004 S 371 (c)(1) WO WO-2004/078756 9, 2004 (2), (4) Date: Mar. 13, 2006 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2004/078757 Denmarket al., “Convergence of Mechanistic Pathways in the Pal PCT Pub. Date: Sep.
    [Show full text]
  • Drug Discovery and Development
    DRUG DISCOVERY AND DEVELOPMENT Volume 2: Drug Development Edited by MUKUND S. CHORGHADE DRUG DISCOVERY AND DEVELOPMENT DRUG DISCOVERY AND DEVELOPMENT Volume 2: Drug Development Edited by MUKUND S. CHORGHADE Copyright © 2007 by John Wiley & Sons, Inc. All rights reserved. Published by John Wiley & Sons, Inc., Hoboken, New Jersey. Published simultaneously in Canada. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifi cally disclaim any implied warranties of merchantability or fi tness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation.
    [Show full text]